CSPC Pharmaceutical Group Limited

SEHK:1093 Rapporto sulle azioni

Cap. di mercato: HK$67.1b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CSPC Pharmaceutical Group Gestione

Gestione criteri di controllo 2/4

CSPC Pharmaceutical Group's Il CEO è Cuilong Zhang, nominato in May2022, e ha un mandato di 2.25 anni. la retribuzione annua totale è CN¥ 13.47M, composta da 5.1% di stipendio e 94.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.034% delle azioni della società, per un valore di HK$ 24.36M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.9 anni e 7.4 anni.

Informazioni chiave

Cuilong Zhang

Amministratore delegato

CN¥13.5m

Compenso totale

Percentuale dello stipendio del CEO5.1%
Mandato del CEO2.3yrs
Proprietà del CEO0.03%
Durata media del management2.9yrs
Durata media del Consiglio di amministrazione7.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Aug 08
CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Jun 17
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29
CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

May 21
CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

Apr 29
CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Apr 22
There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

Apr 01
CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 22
CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Jan 04
Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Oct 22
Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

Sep 21
Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Jul 09
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

Jun 20
Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 01
CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Apr 04
CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Mar 12
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

Dec 26
We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 98% Above Its Share Price

Oct 18
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 98% Above Its Share Price

CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt

Sep 15
CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At CN¥0.10

Aug 26
CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At CN¥0.10

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Cuilong Zhang rispetto agli utili di CSPC Pharmaceutical Group?
DataCompenso totaleStipendioGuadagni aziendali
Mar 31 2024n/an/a

CN¥6b

Dec 31 2023CN¥13mCN¥693k

CN¥6b

Sep 30 2023n/an/a

CN¥6b

Jun 30 2023n/an/a

CN¥6b

Mar 31 2023n/an/a

CN¥6b

Dec 31 2022CN¥11mCN¥693k

CN¥6b

Sep 30 2022n/an/a

CN¥6b

Jun 30 2022n/an/a

CN¥6b

Mar 31 2022n/an/a

CN¥6b

Dec 31 2021CN¥9mCN¥693k

CN¥6b

Sep 30 2021n/an/a

CN¥6b

Jun 30 2021n/an/a

CN¥6b

Mar 31 2021n/an/a

CN¥5b

Dec 31 2020CN¥9mCN¥693k

CN¥5b

Sep 30 2020n/an/a

CN¥4b

Jun 30 2020n/an/a

CN¥4b

Mar 31 2020n/an/a

CN¥4b

Dec 31 2019CN¥7mCN¥693k

CN¥4b

Sep 30 2019n/an/a

CN¥4b

Jun 30 2019n/an/a

CN¥3b

Mar 31 2019n/an/a

CN¥3b

Dec 31 2018CN¥4mCN¥298k

CN¥3b

Compensazione vs Mercato: La retribuzione totale di Cuilong ($USD 1.89M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 913.61K ).

Compensazione vs guadagni: La retribuzione di Cuilong è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Cuilong Zhang (55 yo)

2.3yrs

Mandato

CN¥13,472,000

Compensazione

Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Dongchen Cai
Executive Chairman27.3yrsCN¥26.68m23.78%
CN¥ 16.0b
Cuilong Zhang
Vice-Chairman & CEO2.3yrsCN¥13.47m0.034%
CN¥ 22.7m
Chunlei Li
Executive Director & Chief Scientist6.7yrsCN¥9.42m0.038%
CN¥ 25.6m
Weidong Pan
Executive Directorno dataCN¥4.92m0.013%
CN¥ 8.5m
Huaiyu Wang
Executive Directorno dataCN¥5.74m0.013%
CN¥ 8.5m
Zhenguo Wang
Executive Directorno dataCN¥4.90m0.013%
CN¥ 8.5m
Hao Jiang
Executive Directorno dataCN¥4.02m0.024%
CN¥ 15.9m
Xin Cai
Group Executive Presidentno dataNessun datoNessun dato
Bing Yao
Executive Directorless than a yearNessun datoNessun dato
Tai On Lo
Company Secretary3.6yrsNessun datoNessun dato

2.9yrs

Durata media

54.5yo

Età media

Gestione esperta: Il team dirigenziale di 1093 è considerato esperto (durata media dell'incarico 2.9 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Dongchen Cai
Executive Chairman27.3yrsCN¥26.68m23.78%
CN¥ 16.0b
Cuilong Zhang
Vice-Chairman & CEO6.1yrsCN¥13.47m0.034%
CN¥ 22.7m
Chunlei Li
Executive Director & Chief Scientist6.7yrsCN¥9.42m0.038%
CN¥ 25.6m
Weidong Pan
Executive Director17.8yrsCN¥4.92m0.013%
CN¥ 8.5m
Huaiyu Wang
Executive Director13.8yrsCN¥5.74m0.013%
CN¥ 8.5m
Zhenguo Wang
Executive Director12.6yrsCN¥4.90m0.013%
CN¥ 8.5m
Hao Jiang
Executive Director3.8yrsCN¥4.02m0.024%
CN¥ 15.9m
Xin Cai
Group Executive Presidentless than a yearNessun datoNessun dato
Bing Yao
Executive Directorless than a yearNessun datoNessun dato
Chun Kwok Au
Independent Non-Executive Director3.6yrsCN¥340.00kNessun dato
Bo Wang
Independent Non-Executive Director11.7yrsCN¥142.00kNessun dato
Chuan Chen
Independent Non-Executive Director8.2yrsCN¥142.00kNessun dato

7.4yrs

Durata media

54.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1093 sono considerati esperti (durata media dell'incarico 7.4 anni).